Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a leading medical device company dedicated to providing non-invasive and cost-effective treatments for non-melanoma skin cancer and keloids. Utilizing a proprietary low-energy x-ray radiation technology known as Superficial Radiation Therapy (SRT), Sensus Healthcare has made significant advancements in the field over more than a decade of dedicated research and development. The company’s flagship products, the SRT-100™ and SRT-100 Vision™, effectively and safely treat a variety of oncological and non-oncological skin conditions, including basal cell and squamous cell skin cancers, as well as keloids.
Based in Boca Raton, Florida, Sensus Healthcare focuses on creating innovative, minimally-invasive solutions that address critical medical needs. The company has recently announced a multi-faceted collaboration with CureRays, a radiation oncology specialist organization headquartered in Atlanta and Grass Valley, California. This partnership aims to enhance the reach and efficacy of Sensus's SRT technology, further solidifying its position as a leader in the non-invasive treatment market.
Sensus Healthcare generates the majority of its revenue from customers within the United States, offering products and services that meet the highest standards of safety and effectiveness. The company’s proprietary technology has been incorporated into its diverse portfolio, which includes the SRT-100™, SRT-100 Vision™, and a comprehensive Sentinel service program that ensures optimal device performance and customer satisfaction.
Investors and stakeholders are encouraged to stay informed about Sensus Healthcare’s latest developments. Recently, the company announced it would hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones. This call will offer an in-depth overview of the company’s financial health and strategic initiatives.
For more detailed information about Sensus Healthcare, its innovative technology, products, and recent news, please visit Sensus Healthcare’s official website.
Sensus Healthcare, Inc. announces the sale of the first SRT-100 Vision™ system in Asia to Far Eastern Memorial Hospital in Taiwan. The hospital plans to conduct research on new indications for the system, potentially leading to global label expansion. The company is optimistic about future sales in the region and emphasizes the importance of this sale. The SRT-100 Vision system utilizes image-guided ultrasound technology and has seen recent enhancements for improved clinical outcomes. Additionally, Sensus Healthcare will host a conference call on May 9, 2024, to discuss first-quarter financial results and provide business updates.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What is Sensus Healthcare, Inc.?
What products does Sensus Healthcare offer?
What is Superficial Radiation Therapy (SRT)?
Where is Sensus Healthcare based?
What recent collaborations has Sensus Healthcare announced?
How does Sensus Healthcare generate its revenue?
What is the Sentinel service program?
When is the next conference call for Sensus Healthcare?
Where can I find more information about Sensus Healthcare?
What conditions can Sensus Healthcare’s devices treat?
